Program & Replays

Reflections on 40 Years in the Psychedelic Space: Research, Clinical Practice & Transformation

Broadcast on May 09, 2023
With Scott Shannon, MD
Hosted by Joe Tafur, MD

Scott Shannon, MD, will share changes he's observed in the psychedelic space over the past 40 years, including research, clinical practices, and how MDMA is used. He'll also discuss how ketamine is being used today as a transformative agent for conventional mental healthcare, and how the legalization of psilocybin in Colorado will accelerate clinical innovation as well as risk.

In this session, you’ll discover:

  • MDMA has the potential to be applied much more widely than just in treating PTSD
  • Ketamine is an effective entry point to psychedelic practice and an excellent tool for training professionals
  • Psilocybin is powerful and will be difficult to apply consistently in clinical practice
The opinions expressed here are those of the author/presenter and are not representative of Shift Network employees, customers, or other presenters.
The replay has expired. Upgrade to get full access.
If you‘ve already purchased the upgrade package, access it here.

Love this Speaker and What They Have to Say?

It can be yours to keep... forever.

Get lifetime access to the summit and bonus material by upgrading now!

UPGRADE HERE

NEED HELP? CLICK HERE FOR SUPPORT

Scott Shannon, MD

Assistant Clinical Professor of Psychiatry, University of Colorado.

Scott Shannon, MD, has been a student of consciousness since he wrote his honor’s thesis on that topic at the University of Arizona in the 1970s. Following medical school, MDMA-assisted psychotherapy became a facet of his practice before this medicine was restricted by the Drug Enforcement Administration (DEA) in 1985. He then completed a psychiatry residency at Columbia University in New York City. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico. He's published four books on holistic and integrative mental health, including the very first textbook written for this field in 2001. 

Scott is a past president of the American Holistic Medical Association and a past president of the American Board of Integrative Holistic Medicine. He serves as a site principal investigator and therapist for the Phase III trial of MDMA-assisted psychotherapy for PTSD, and for a Phase IIb study of LSD in generalized anxiety disorder. He has also published numerous articles about his research on cannabidiol (CBD) in mental health. Scott founded the Psychedelic Research and Training Institute (PRATI) to train professionals in ketamine-assisted psychotherapy, and deliver clinically relevant studies.  He lectures all over the world to professional groups interested in a paradigm-shifting perspective about transformative care. 

02Psychedelics02_23
ProgramPage
54712
Scott Shannon, MD
Session
s0xnk5